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Abstract 
Background: Individuals with peripheral artery disease (PAD) often have reduced physical activity, which may 
increase the future risk of diabetes mellitus. Although diabetes is a risk factor for PAD, whether low ankle-brachial 
index (ABI) predates diabetes has not been studied.
Methods: We examined the association of ABI with incident diabetes using Cox proportional hazards models in the 
ARIC Study. ABI was measured in 12,247 black and white participants without prevalent diabetes at baseline (1987–
1989). Incident diabetes cases were identified by blood glucose levels at three subsequent visits (1990–92, 1993–95, 
and 1996–98) or self-reported physician diagnosis or medication use at those visits or during annual phone interview 
afterward through 2011.
Results: A total of 3305 participants developed diabetes during a median of 21 years of follow-up. Participants with 
low (≤0.90) and borderline low (0.91–1.00) ABI had 30–40% higher risk of future diabetes as compared to those with 
ABI of 1.10–1.20 in the demographically adjusted model. The associations were attenuated after further adjustment 
for other potential confounders but remained significant for ABI 0.91–1.00 (HR = 1.17, 95% CI 1.04–1.31) and margin-
ally significant for ABI ≤ 0.90 (HR = 1.19, 0.99–1.43). Although the association was largely consistent across subgroups, 
a stronger association was seen in participants without hypertension, those with normal fasting glucose, and those 
with a history of stroke compared to their counterparts.
Conclusions: Low ABI was modestly but independently associated with increased risk of incident diabetes in the 
general population. Clinical attention should be paid to the glucose trajectory among people with low ABI but with-
out diabetes.
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cohort study
© The Author(s) 2016. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Lower extremity peripheral arterial disease (PAD), typi-
cally defined by an ankle-brachial index (ABI) < 0.9 [1], 
affects 8–10 million people in the United States [2]. PAD 
increases the risk of cardiovascular disease and reduces 
quality of life due to ischemic leg pain and intermittent 
claudication [1, 3, 4].
Regardless of leg symptoms, patients with PAD expe-
rience functional decline and impairment [5–7], which 
are shown to result in reduced level of physical activity 
[8, 9]. For example, a study observed a 20% decline in 
accelerometer-measured physical activity level in par-
ticipants with PAD comparing to those without [8]. Since 
physically inactivity is an important risk factor of diabe-
tes mellitus [10], it is possible that low ABI is associated 
with the development of diabetes. Furthermore, ABI, 
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an indicator of severity of atherosclerosis in the legs, is 
found to be associated with microvascular dysfunction in 
skeletal muscle which is the largest tissue in the body that 
is insulin-sensitive and central to glucose utilization and 
metabolic health [11, 12].
However, to the best of our knowledge, the associa-
tion of ABI with future risk of diabetes has not yet been 
studied although the opposite direction of association 
(i.e., diabetes as a risk factor of PAD) is well-known [2, 
13, 14]. Therefore, we aimed to investigate whether ABI 
is independently associated with incident diabetes in a 
community-based cohort, the Atherosclerosis Risk in 
Communities (ARIC) Study.
Methods
Study population
The ARIC Study is a community-based prospective 
cohort study of 15,792 individuals aged 45–64  years at 
baseline. Participants were recruited at baseline exami-
nation (visit 1) during 1987–1989 from four US com-
munities: Forsyth County, North Carolina; Jackson, 
Mississippi; suburbs of Minneapolis, Minnesota; and 
Washington County, Maryland [15]. The participants 
were invited for three short-term follow-up examinations 
at three-year intervals (visits 2 [1990–1992], 3 [1993–
1995], and 4 [1996–1998]). They also received annual 
telephone interview regarding their lifestyle and clinical 
conditions. The study was approved by the institutional 
review boards at all centers, and informed consent was 
obtained from all participants.
Of 15,792 participants, we excluded 2309 participants 
with prevalent diabetes (defined as self-reported physi-
cian diagnosis or treatment of diabetes, fasting blood 
glucose ≥126 mg/dl or random blood glucose ≥200 mg/
dl at baseline) and 17 participants with no information 
about diabetes status. We further excluded 40 non-white 
and non-black participants as well as those with missing 
information on ABI (n = 476) and any covariates at base-
line (n = 596), leaving 12,247 participants in our analy-
sis. Of the study population, 76% participants attended 
all follow-up visits 2 through 4 while 88% attended at 
least two follow-up visits and 97% attended at least once. 
Approximately 92% participants responded to annual tel-
ephone interview after visit 4 examination.
Exposure assessment
ABI was defined as a ratio of systolic blood pressure of 
ankle to that of arm. The ankle and brachial blood pres-
sures were measured by Dinamap Model 1846 SX dur-
ing ultrasound assessment, an oscillometric device that 
obtains repeated blood pressure measurement automati-
cally [3, 16]. Before examination, participants were asked 
to refrain from smoking, vigorous exercise, and drinking 
coffee, tea, and soft drinks containing caffeine during the 
night before and the day of examination [16]. Ankle sys-
tolic blood pressure was measured four times in a ran-
domly selected leg and the last non-missing value was 
used as numerator of ABI. Brachial systolic blood pres-
sure was measured twice in the right arm and the first 
non-missing value was used as denominator of ABI [17]. 
According to a previous study, the reliability of the ABI 
based on single ankle and arm systolic blood pressure 
was 0.61 (95% CI 0.50, 0.70) [18].
Outcome assessment
The ascertainment of incident diabetes mellitus was 
based on two elements, self-reported physician diagnosis 
or treatment of diabetes during visits or phone interview 
through April 18, 2011 (interview-based definition) and 
fasting blood glucose ≥126 mg/dl (7.0 mmol/l), random 
blood glucose ≥200 mg/dl (11.1 mmol/l), or self-reported 
physician diagnosis or treatment of diabetes during vis-
its 2 through 4 (visit-based definition), as previously done 
[19]. Participants who did not develop diabetes during 
follow-up were censored due to death, loss to follow-up, 
or end of follow-up. To maximize the statistical power, as 
the primary outcome, we combined these two definitions 
but also analyzed them separately as a secondary analysis.
Covariates of interest
Age, gender, race, parental history of diabetes, medi-
cal history of coronary heart disease (CHD) and stroke/
transient ischemic attack (TIA), smoking and alco-
hol drinking habits and exertional leg pain were self-
reported at baseline. Medication use was assessed by 
self-report and examination of medication contain-
ers brought to the visit. Height, weight, and sitting 
blood pressure were measured according to standard-
ized protocols. Hypertension was defined as a systolic 
blood pressure  ≥140  mmHg or a diastolic blood pres-
sure ≥90 mmHg, or use of antihypertensive drugs. Total 
cholesterol level, high-density lipoprotein cholesterol 
level, and triglyceride level were measured using enzy-
matic determination methods. Glucose was measured 
using the hexokinase-glucose-6-phosphate dehydroge-
nase method, as detailed previously [19]. White blood 
cell count was measured by automated hematology ana-
lyzer [20]. Fibrinogen was measured using assay accord-
ing to standard procedures [21]. Physical activity was 
assessed with the Baecke physical activity questionnaire, 
which recorded the duration, intensity and frequency 
of physical activity at work, in leisure time and during 
sports and produced an index score to represent level of 
physical activity [22].
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Statistical analyses
We categorized ABI into seven groups, ABI  ≤  0.90, 
0.90  <  ABI  ≤  1.00 (denoted as 0.91–1.00), 1.01–1.10, 
1.11–1.20, 1.21–1.30, 1.31–1.40 and  >1.40, consistent 
with prior literature [3]. Baseline characteristics were 
compared across these groups, according to Chi square 
test and ANOVA, as appropriate.
To visualize potentially non-linear associations, we 
estimated incidence rates of diabetes according to ABI 
with its linear spline terms (knots at 0.9, 1.0, 1.1, 1.2, 1.3 
and 1.4) using Poisson regression models. We subse-
quently quantified the adjusted risk of incident diabetes 
according to the seven ABI categories using Cox propor-
tional hazards models. ABI 1.11–1.20 was used as the 
reference group since this group was used as the refer-
ence in an international meta-analysis and had the larg-
est number of participants in our study [23]. To evaluate 
the impact of potential confounding, we constructed 
three models. Model 1 was adjusted for age, sex and 
race. Model 2 included all variables in Model 1 plus fac-
tors associated with atherosclerosis and diabetes, namely 
body mass index, total cholesterol, high-density lipopro-
tein cholesterol, and triglyceride, drinking and smok-
ing status (current, former, and never), systolic blood 
pressure, hypertension medication use, history of CHD, 
stroke or TIA, statin use, parental history of diabetes, 
white blood cell count, and physical activity index. Mod-
els 3 and 4 included all variables in Model 2 plus base-
line fasting glucose or homeostatic model assessment 
of insulin resistance (HOMA-IR), respectively. There 
was no major deviation from the proportional hazards 
assumption for ABI categories based on visual evalua-
tion from log–log plot as well as from test on Schoenfeld 
residuals.
To evaluate whether the association is consistent 
across demographic and clinical subgroups, we tested 
for interaction and conducted subgroup analyses by age 
(≤vs. >55 years), gender, race, smoking status (current vs. 
former/never), history of cardiovascular disease, history 
of stroke or TIA, hypertension status, baseline fasting 
glucose level [normal  <100 (<5.6  mmol/l) vs. impaired 
100–125 mg/dl (5.6–6.9 mmol/l)] and exertional leg pain 
status. Interaction was tested by incorporating a product 
term of ABI categories and subgroups in Cox models.
As a sensitivity analysis, we repeated the analysis in 
visit-based definition and interview-based definition of 
diabetes separately. We also explored the model which 
replaced white blood cell count with fibrinogen (an 
alternative inflammatory marker) in Model 2. Finally, 
we treated physical activity, a potential mediator of ABI-
diabetes association, as a time-varying covariate using 
self-report data assessed at visit 3 in addition to Model 2 
covariates.
All analyses were performed with Stata version 12.0. 
All p values were two-sided, and p < 0.05 was considered 
statistically significant.
Results
The mean ABI of study population was 1.13 (SD 0.14). 
There were 455 individuals (3.7%) with ABI  ≤  0.90 
and 1529 participants (12.5%) with borderline low 
ABI of 0.91–1.00. There was no significant correlation 
between ABI and baseline fasting glucose (r =  0.002, p 
value  =  0.81). Baseline characteristics of study partici-
pants by ABI categories are shown in Table  1. As com-
pared to participants with ABI 1.11–1.20 (reference 
group), those with lower ABI were more likely to be older, 
female, and blacks. They also had worse cardiovascular 
risk profiles relative to the reference group, including 
higher prevalence of current smokers, hypertension, and 
cardiovascular diseases (CHD and stroke/TIA), higher 
levels of body mass index, total cholesterol, triglyceride, 
white blood cell count, and fibrinogen, and lower level 
of physical activity. Participants with ABI > 1.40, indica-
tive of arterial calcification [24], also had worse car-
diovascular risk profiles as compared to those with ABI 
1.11–1.20. The fasting glucose levels are similar across 
ABI categories. However, participants with ABI  ≤  0.90 
and ABI  >  1.40 had higher levels of fasting insulin and 
HOMA-IR than the rest groups.
A total of 3305 cases of incident diabetes were identi-
fied during a median of 21 years of follow-up (incidence 
rate 16.8 [95% CI 15.8–16.9] per 1000 person-years). Fig-
ure 1 shows demographically adjusted incidence rates of 
diabetes according to ABI at baseline. The incidence rates 
of diabetes were lowest in ABI 1.10–1.30 and increased 
below this range. The incidence rate of diabetes was 
similar or slightly higher in ABI > 1.30 compared to ABI 
1.10–1.30.
In a demographically adjusted Cox regression model 
with ABI 1.10–1.20 as the reference, lower ABI categories 
were significantly associated with incident diabetes (haz-
ard ratio [HR] 1.41 [95% CI 1.17–1.68] for ABI ≤  0.90, 
1.29 [1.15–1.45] for ABI 0.91–1.00, and 1.10 [1.00–1.22] 
for ABI 1.01–1.10, Model 1 in Table 2). When we further 
adjusted for other potential confounders including tradi-
tional cardiovascular risk factors, white blood cell count, 
and physical activity (Model 2 in Table  2), the associa-
tions for all lower ABI categories remained significant 
although it was borderline significant for ABI ≤ 0.90. The 
replacement of white blood cell count with fibrinogen 
did not make material difference (data not shown). After 
accounting for baseline fasting glucose (Model 3), the 
association remained marginally significant only in par-
ticipants with ABI 0.91–1.00 (p value = 0.051). However, 
when we combined low ABI ≤  0.90 and borderline low 
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0.91–1.00 groups, the association was statistically sig-
nificant even in Model 3 (HR = 1.12 [95% CI 1.01–1.24], 
p value =  0.034). The associations between ABI ≤  0.90 
and ABI 0.91–1.00 with incident diabetes were slightly 
stronger than those in model 3 when we further adjusted 
for HOMA-IR in addition to model 2 (Model 4). For 
participants with ABI  >  1.40, we observed slight but 
non-significant increase in the risk of incident diabetes 
compared to those with ABI 1.11–1.20 in Models 1 and 3. 
The association was largely consistent when we analyzed 
interview-based cases and visit-based cases separately 
(Additional file 1: Tables S1, S2). The model with physi-
cal activity as a time-varying covariate using visit 3 data 
showed similar results (data not shown).
Table 1 Baseline characteristics of participants without prevalent diabetes by ABI categories
ABI ankle-brachial index, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, TIA transient ischemic attack, CHD coronary heart disease, 
HDL high density cholesterol, HOMA-IR homeostatic model assessment of insulin resistance
a Indicates statistically significant difference among ABI groups
Characteristics ABI ≤ 0.90 0.91–1.00 1.01–1.10 1.11–1.20 1.21–1.30 1.31–1.40 ABI > 1.40
N (%) 455 (3.7) 1529 (12.5) 2894 (23.6) 3633 (29.7) 2509 (20.5) 924 (7.5) 303 (2.5)
Age, mean (SD), 
yearsa
54.9 (5.9) 53.7 (5.8) 53.4 (5.6) 53.9 (5.8) 53.9 (5.6) 54.6 (5.7) 55.1 (5.7)
Female, no. (%)a 321 (70.6) 1116 (73.0) 1867 (64.5) 1903 (52.4) 1104 (44.0) 373 (40.4) 125 (41.3)
Black, no. (%)a 121 (26.6) 357 (23.4) 700 (24.2) 867 (23.9) 542 (21.6) 177 (19.2) 47 (15.5)
BMI, mean (SD), kg/
m2a
27.7 (6.0) 27.7 (5.8) 27.1 (5.2) 27.0 (4.7) 27.0 (4.6) 27.4 (4.8) 28.3 (5.5)
Height, mean (SD), 
cma
165.2 (8.9) 165.5 (8.5) 167.0 (9.0) 169.2 (9.3) 170.5 (9.3) 171.4 (9.5) 170.3 (9.5)
Current drinker, no. 
(%)a
244 (53.6) 874 (57.2) 1698 (58.7) 2189 (60.3) 1525 (60.8) 550 (59.5) 163 (53.8)
Current smoker, no. 
(%)a
167 (36.7) 440 (28.8) 798 (27.6) 855 (23.5) 602 (24.0) 195 (21.1) 63 (20.8)
Arm SBP, mean (SD), 
mmHga
123.0 (19.7) 121.0 (19.2) 120.3 (18.8) 119.7 (17.5) 118.2 (16.6) 118.0 (15.8) 117.6 (15.3)
Heart rate. mean 
(SD), /mina
68.5 (11.4) 67.7 (10.5) 66.9 (9.7) 65.8 (9.6) 64.5 (9.6) 64.3 (9.4) 64.2 (9.8)
Hypertension medi-
cation, no. (%)a
169 (37.1) 449 (29.4) 810 (28.0) 932 (25.7) 587 (23.4) 221 (23.9) 95 (31.4)
Prevalent CHD, no. 
(%)a
30 (6.6) 68 (4.5) 103 (3.6) 137 (3.8) 103 (4.1) 38 (4.1) 20 (6.6)
History of stroke or 
TIA, no. (%)a
33 (7.3) 68 (4.5) 123 (4.3) 151 (4.2) 99 (4.0) 26 (2.8) 15 (5.0)
Total cholesterol, 
mean (SD), mmol/la
5.8 (1.1) 5.6 (1.0) 5.6 (1.1) 5.5 (1.1) 5.5 (1.0) 5.5 (1.0) 5.5 (1.1)
HDL, mean (SD), 
mmol/la
1.4 (0.5) 1.4 (0.5) 1.4 (0.5) 1.4 (0.4) 1.3 (0.4) 1.3 (0.4) 1.3 (0.4)
Triglyceride, median 
(IQR), mmol/la
1.3 (0.9–1.8) 1.2 (0.9–1.6) 1.2 (0.8–1.6) 1.2 (0.9–1.7) 1.2 (0.9–1.7) 1.2 (0.9–1.7) 1.3 (0.9–1.8)
Statin use, no. (%) 5 (1.1) 13 (0.9) 16 (0.6) 12 (0.3) 9 (0.4) 5 (0.5) 2 (0.7)
Fasting glucose, 
mean (SD), mmol/l
5.5 (0.5) 5.5 (0.5) 5.5 (0.5) 5.5 (0.5) 5.5 (0.5) 5.5 (0.5) 5.5 (0.5)
Fasting insulin, 
median (25, 75%), 
pmol/la
71.8 (43.1–107.6) 64.6 (43.1–100.5) 64.6 (43.1–93.3) 64.6 (43.1–93.3) 64.6 (43.1–93.3) 64.6 (43.1–93.3) 71.8 (43.1–107.6)
HOMA-IR, median 
(25, 75%)a
2.8 (1.8–4.3) 2.6 (1.7–4.0) 2.5 (1.6–4.0) 2.5 (1.6–3.9) 2.5 (1.7–3.8) 2.6 (1.7–4.0) 2.8 (1.7–4.6)
Parental history of 
diabetes, no. (%)
104 (22.9) 363 (23.7) 633 (21.9) 809 (22.3) 580 (23.1) 190 (20.6) 76 (25.1)
White blood cell 
count, median (25, 
75%), 103a
6.3 (5.1–7.5) 5.9 (4.9–7.2) 5.8 (4.8–7.0) 5.6 (4.7–6.9) 5.6 (4.7–6.9) 5.7 (4.7–6.8) 5.6 (4.7–6.9)
Fibrinogen, median 
(25, 75%), mg/dla
314 (277–362) 295 (261–342) 295 (260–336) 288 (255–327) 285 (255–324) 286 (254–323) 294 (261–333)
Physical activity 
index, mean (SD)a
6.7 (1.5) 6.9 (1.5) 7.0 (1.4) 7.1 (1.4) 7.2 (1.4) 7.2 (1.4) 7.2 (1.5)
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To obtain reliable estimates in subgroup analyses, 
we dichotomized ABI at below and above 1.00. Given 
slight increase in the risk of diabetes in some models, 
those with ABI  >  1.40 were excluded from this analy-
sis. We observed significant difference in participants 
with vs. without history of stroke/TIA (HR 1.56 [95% 
CI 1.09–2.24] vs. 1.05 [0.95–1.15], p value for interac-
tion = 0.034) and in those with vs. without hypertension 
(HR 0.96 [0.84–1.10] vs. 1.18 [95% CI 1.05–1.33], p value 
for interaction = 0.024) (Table 3). We also observed bor-
derline significant difference between those with normal 
vs. impaired fasting glucose (HR 1.20 [95% CI 1.04–1.39] 
vs. 1.01 [0.90–1.14], p value for interaction  =  0.067). 
The higher risk of diabetes was confirmed for both ABI 
categories of  ≤0.90 and 0.91–1.00 in participants with 
normal fasting glucose, those without hypertension, and 
those with a history of stroke/TIA (Additional file  1: 
Tables S3, S4, S5).
Discussion
To our knowledge, this is the first study to examine the 
association between ABI and the future risk of diabetes. 
We found that low and borderline low ABI (≤1.0) was asso-
ciated with a moderately increased risk of diabetes. The 
association was independent of other atherosclerotic car-
diovascular diseases, physical activity, and other potential 
confounders. Further adjustment for fasting glucose levels 
attenuated the association, but ABI ≤  1.0 showed signifi-
cantly higher risk of diabetes compared to ABI 1.11–1.20 
even in this model. Largely similar results were observed in 
demographic and clinical subgroups, although the associa-
tions tended to be stronger in participants without hyper-
tension, those with normal fasting glucose, and those with 
history of stroke/TIA compared to their counterparts.
In terms of potential mechanisms, as we hypothesized, 
impaired physical activity related to PAD may play a role. 
However, in our study, the ABI-diabetes relationship 
remained significant after accounting for physical activ-
ity. Yet, we need to bear in mind that physical activity 
was based on self-report [25]. Also, there are a few other 
potential mechanisms linking low ABI to future diabetes 
risk. ABI is a marker of systematic atherosclerosis [26], 
and participants with low ABI indeed had worse cardio-
vascular risk profiles in our study. Several traditional car-
diovascular risk factors such as hypertension, smoking, 
and dyslipidemia are known to be related to high risk of 
developing diabetes [27–29]. Thus, we rigorously adjusted 
for these traditional risk factors but still observed signifi-
cant associations between ABI and risk of diabetes. Also, 
endothelial dysfunction, an early condition of atheroscle-
rosis, may be a contributor. It has been shown that delayed 
insulin delivery can occur due to endothelial dysfunction 
[30]. Indeed, endothelial dysfunction is associated with 
future risk of type 2 diabetes in a few studies [31, 32]. In 
addition, shared pathophysiology such as inflammation is 
Fig. 1 Demographically adjusted incidence rates of diabetes accord-
ing to ABI and distribution of ABI. Graphed for 0.5–99.5 percentile of 
ABI values. Adjusted to mean age, white and male
Table 2 Hazard ratios of diabetes in different ABI categories
Model 1, adjusted for age, gender and race; Model 2, adjusted for age, gender, race, current and former drinking, current and former smoking, BMI, SBP, hypertension 
medication, HDL, total cholesterol, log (triglyceride), prevalent CHD, stroke or TIA, statin use, parental history of diabetes, log (white blood cell count) and Baecke 
physical activity index; Model 3, adjusted for baseline fasting glucose in addition to model 2; Model 4, adjusted for baseline log (HOMA-IR) in addition to model 2
ABI ≤0.90 0.91–1.00 1.01–1.10 1.11–1.20 1.21–1.30 1.31–1.40 >1.40
N 12,247 455 1529 2894 3633 2509 924 303
Number of events 3305 137 457 781 927 668 249 86
Model 1 HR 1.41 1.29 1.10 Ref 1.06 1.07 1.16
95% CI 1.17–1.68 1.15–1.45 1.00–1.22 – 0.96–1.17 0.93–1.23 0.93–1.45
Model 2 HR 1.20 1.17 1.10 Ref 1.08 1.10 1.01
95% CI 0.99–1.43 1.04–1.31 1.00–1.21 – 0.98–1.20 0.96–1.27 0.81–1.27
Model 3 HR 1.12 1.12 1.08 Ref 1.06 1.09 1.12
95% CI 0.94-1.34 0.99–1.26 0.98–1.18 – 0.96–1.17 0.94–1.25 0.90–1.40
Model 4 HR 1.18 1.14 1.09 Ref 1.09 1.10 1.00
95% CI 0.98–1.41 1.02–1.28 0.99–1.20 – 0.99–1.21 0.95–1.26 0.80–1.25
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known for atherosclerosis and insulin resistance [33, 34]. 
Although chronic inflammation can be a common ground 
for development of both atherosclerosis and diabetes [33–
36], our results were not altered with adjustment for white 
blood cell count or fibrinogen.
We found that the association between low and bor-
derline low ABI (≤1.00) and risk of diabetes tended to be 
stronger in participants without hypertension, those with 
normal fasting glucose, and those with a history of stroke/
TIA as compared to their counterparts. We are not nec-
essarily sure about mechanisms behind these suggestive 
interactions, but there may be a few potential explanations 
for null association in participants with hypertension or 
elevated glucose level. Many of those with hypertension 
were treated with antihypertensive medications (72%), 
which might confound the ABI-diabetes association to 
null among hypertensive patients. Indeed, renin-angi-
otensin system inhibitors are reported to reduce the risk 
of diabetes [37], whereas diuretics and beta blockers may 
contribute to increased risk of developing diabetes [38]. 
For people with impaired fasting glucose, who are known 
to have reduced insulin sensitivity and β cell dysfunction 
[39], a mild single predictor such as ABI may not consider-
ably contribute to discriminating their diabetes risk since 
they are already at high risk of diabetes. Nonetheless, we 
need to keep in mind that we have tested multiple sub-
groups without a priori hypothesis, and thus, our subgroup 
analysis should be interpreted as hypothesis-generating.
Clinical and research implications of the study
Although our findings need to be confirmed in other set-
tings, there may be a few clinical and research implica-
tions from our study. Our study demonstrates future 
diabetes as another adverse clinical consequence of PAD 
in addition to its known complications such as other car-
diovascular diseases and impaired functional status [3, 4, 
7, 26, 40–44]. This finding is important given the adverse 
outcomes associated with diabetes [44–49]. Since some 
clinical guidelines recommend screening of PAD using 
the ABI in individuals with advanced age and/or tradi-
tional cardiovascular risk factors [1, 50], attention should 
be given to monitoring glucose levels among individuals 
with low or borderline low ABI even though their fast-
ing glucose is within the normal range at baseline. If 
our results are replicated, it would be worth assessing 
whether PAD-specific interventions (e.g., supervised 
exercise [51]) have beneficial effects on glucose metabo-
lism and whether other measures of subclinical athero-
sclerosis (e.g., carotid intra-media thickness or coronary 
artery calcium) are related to incident diabetes.
Limitations of the study
Our study has several limitations. First, ABI was meas-
ured once for a randomly selected leg at baseline. The 
prevalence of low ABI may be underestimated as a 
result of missing low ABI in the opposite leg in some 
participants. Second, there were 15  years of follow-up 
where incident diabetes cases were solely based on self-
report (interview-based definition). However, as afore-
mentioned, the association was largely consistent for 
Table 3 Hazard ratios of diabetes in different subgroups
N = 11,944
Excluded ABI > 1.4 and adjusted for age, gender, race, current and former 
drinking, current and former smoking, BMI, SBP, hypertension medication, HDL, 
total cholesterol, log (triglyceride), prevalent CHD, stroke or TIA, statin use, 
parental history of diabetes, log (white blood cell count), Baecke physical activity 
index and fasting glucose
Subgroup HR and 95% CI 
ABI ≤ 1.00 vs 1.01–1.40
p value for inter-
action
All 1.07 (0.98, 1.17) –
Gender 0.46
 Male (5260) 1.13 (0.96–1.33)
 Female (6684) 1.05 (0.94–1.17)
Race 0.89
 White (9180) 1.08 (0.97–1.20)
 Black (2764) 1.06 (0.90–1.25)
Age 0.35
 ≤55 (7193) 1.04 (0.92–1.17)
 >55 (4751) 1.13 (0.98–1.30)
Current smoking 0.77
 No (8887) 1.07 (0.96–1.19)
 Yes (3057) 1.10 (0.93–1.30)
Prevalent CHD 0.41
 No (11,465) 1.08 (0.99–1.19)
 Yes (479) 0.89 (0.58–1.39)
History of stroke/TIA 0.034
 No (11,444) 1.05 (0.95–1.15)
 Yes (500) 1.56 (1.09–2.24)
Hypertension 0.024
 No (8923) 1.18 (1.05–1.33)
 Yes (3622) 0.96 (0.84–1.10)
Family history of 
diabetes
0.37
 No (9625) 1.04 (0.93–1.16)
 Yes (2679) 1.14 (0.97–1.34)
Baseline FBG 
5.6–6.9 mmol/l
0.067
 No (6895) 1.20 (1.04–1.39)
 Yes (5049) 1.01 (0.90-1.14)
Leg pain while walk-
ing
0.58
 No (9606) 1.05 (0.95–1.17)
 Yes (2338) 1.12 (0.94–1.33)
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visit-based and interview-based diabetes. Third, we were 
not able to adjust for baseline hemoglobin A1c as it was 
not available at visit 1. Fourth, our study participants 
were 45–64 years old at baseline, and thus the generaliza-
tion of our results to adults in other age ranges should be 
done with caution. Finally, like other observational stud-
ies, residual confounding cannot be denied.
Conclusions
Low ABI (≤1.00) was modestly but independently associ-
ated with increased risk of future diabetes in community-
based middle-aged populations. Although future studies 
are needed to confirm our findings and investigate poten-
tial mechanisms, our study suggests that clinical atten-
tion should be given to glucose trajectory in people with 
low or borderline low ABI.
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